Providers/Grant Support
This activity is supported by educational grants from Johnson & Johnson and Lilly.
Credits Available
- Physicians — maximum of 2.5 AMA PRA Category 1 Credits™
- Nurses — 2.5 ANCC contact hours
- Pharmacists — 2.5 hours
All other healthcare professionals completing this course will be issued a statement of participation.
*Learners should claim credit only after viewing all of the course content in this 10-part series in which they wish to participate. Once credit is claimed for this course, it will not be possible to claim additional credit.
Target Audience
This activity was developed for medical oncologists and clinical researchers involved in the management of patients with non-small cell lung cancer (NSCLC) requiring systemic therapy. The interprofessional, multidisciplinary care team (nurses, advanced practice providers, pharmacists, pathologists) will all benefit from updated education and insights into key clinical trials and clinical practice guideline updates that are transforming the care of patients with NSCLC.
Program Overview
Keeping up with new information about non-small cell lung cancer (NSCLC) is daunting. Digesting and applying new information to clinical practice, that’s another hurdle. This accredited series is intended to help clinicians streamline the process. Each month, the editorial board of physician experts in the care of persons with NSCLC reviews the literature to identify 1 or 2 “hot-off-the-press” publications that deserve the spotlight. During a 15-minute peer-to-peer exchange, an editorial board member gains insight from the principal investigator as to why and how the trial was conducted and its implications for clinical practice.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess pharmacology mechanisms and biomarker utilization for novel and emerging therapies for advanced/metastatic NSCLC.
- Describe emerging evidence and clinical data related to treatment advances for patients with metastatic/advanced NSCLC to improve clinician understanding and appreciation for novel therapies.
- Incorporate novel therapies and treatment strategies into the management of patients with advanced/metastatic NSCLC consistent with evolving evidence and practice guidelines.
Faculty
Editorial Board Member: Jamie E. Chaft, MD
Attending Physician
Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Editorial Board Member: Isabel Preeshagul, DO, MBS
Thoracic Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York
Jonathan W. Goldman, MD
Health Sciences Clinical Professor
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Credit
The Annenberg Center designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Credit
The Annenberg Center designates this knowledge-based activity for a maximum of 2.5 hours.
Credit will be provided to NABP CPE Monitor within 45 days after the activity completion.
Nurse Credit
The Annenberg Center designates this education for a maximum of 2.5 American Nurses Credentialing Center (ANCC) contact hours.
Disclosures of Conflict of Interest
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relevant financial relationships with ACCME-defined ineligible companies.
The Annenberg Center assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are mitigated by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
Jamie E. Chaft, MD
- Adjudication Committee: Lilly
- Advisory Board: AstraZeneca, Boehringer Ingelheim, EMD Serono, Exact Sciences, Foundation Medicine, Natera, Nuvation Bio, Revolution Medicines
- Speakers Bureau / Invited Speaker: Merck, Roche-Genentech
- Research Support: AstraZeneca, BioNTech RNA Pharmaceuticals GmbH, Boehringer Ingelheim, Genentech, Merck, Taiho Oncology
- Non-Financial Relationships (Advisory Roles): Boehringer Ingelheim, Lilly, Merck, Taiho Oncology
Isabel Preeshagul, DO, MBS
- Advisory Board: AbbVie, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Nuvalent, Pfizer, Regeneron, Takeda
Jonathan W. Riess, MD, MS
- Advisory Board and Consulting: ArriVent, AstraZeneca, Boehringer Ingelheim, BMS, Daiichi Sankyo, Foundation Medicines, Genentech, GSK, Janssen, Merck, Nuvalent, Nuvation, OncoHost, Pfizer, Regeneron, Replimune, Taiho Pharmaceuticals, Verastem
- Research Support: ArriVent, AstraZeneca, Bicycle Therapeutics, Boehringer Ingelheim, Blossom Hill, IO Biotech, Janssen, Merck, Novartis, Nuvalent, Pfizer, Prelude, Revolution Medicines, Summit Pharmaceuticals.
Additional content planners
Christopher Elder, PharmD, BCOP (Medical Writer)
- Advisory Board: Boehringer Ingelheim, Janssen Scientific/Johnson & Johnson, Mirati and, Pharmacosmos
Beth Sandy, CRNP (Nurse Reviewer)
- Consultant: AbbVie, Boehringer Ingelheim, Nuvation Bio, Pfizer
- Speakers Bureau: Amgen, AstraZeneca, Janssen, Jazz, Lilly, Merck
The following have no relevant financial relationships to disclose:
Rachel Feaster, PharmD, BCOP, BCPS (Peer Reviewer)
Annenberg Center for Health Sciences
All staff at the Annenberg Center have no relevant financial relationships to disclose. All the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
Learners should claim credit only after viewing all of the course content in this 10-part series in which they wish to participate. Once credit is claimed for this course, it will not be possible to claim additional credit.
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center for Health Sciences at Eisenhower disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information
For CME questions please contact: [email protected]